Loading
Distinct shells carrying a filed role for this person — not every shell they have ever touched.
SEC-verified vehicles of the same sponsor, predating these roles and carrying none of them. The badge counts them; the figure beside this one does not.
Mergers closed across all 3 — these vehicles and the franchise's earlier ones together.
Announced but not closed, and still hunting — again over all 3.
No closed vehicle here has both a stored price and a filed trust value to score it against.
1 vehicle on file, newest listing first
none appears on more than one
John Schmid is a Director at Speak, Inc. and serves on the boards of AnaptysBio, Inc., Bright Peak Therapeutics, and Design Therapeutics, Inc.
John P. Schmid currently serves as a member of the board of directors of AnaptysBio, Inc., Bright Peak Therapeutics, and Design Therapeutics, and as chairman of the board of Speak, Inc., a speakers bureau he helped found in 1989. He previously served on the boards of Poseida Therapeutics, Inc., Xeris Pharmaceuticals, Inc., Blacksmith Medicines, Inc. (formerly Forge Therapeutics, Inc.), and Neos Therapeutics. Mr. Schmid was Chief Financial Officer of Auspex Pharmaceuticals, Inc. from 2013 until its sale to Teva Pharmaceuticals, Inc. in 2015, and previously co-founded Trius Therapeutics, Inc., serving as its CFO from 2004 until its merger with Cubist Pharmaceuticals, Inc. in 2013; he also held CFO roles at GeneFormatics, Inc. (1998–2003) and Endonetics, Inc. (1995–1998). He holds a Bachelor's degree in Economics from Wesleyan University and an MBA from the University of San Diego.
[Origin not recorded. Carried over from /people/schmid-john-p-8916, a second record for the same person.]
This record is keyed to SEC CIK 0001478916 — the identifier this person files under in their own name. Every vehicle above is a filing made under that CIK, so “the same person on two shells” is a fact about an SEC identifier rather than about a name that happens to match.
Roles are the strings the filings used, in the order they were filed. Nothing on this page ranks them, infers seniority, or offers a reason why any two of these names recur — a recurrence is a count, and the filings that produced it are linked beside every row. We also hold 10 institutional-holder rows on these vehicles, under 8 distinct name strings, and none of them is counted across vehicles: that table has no CIK column, and matching holders by name would merge firms that are not the same firm.